^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:Triple Negative Breast Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement

    Published date:
    02/14/2022
    Excerpt:
    In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy.
    DOI:
    10.1097/CAD.0000000000001272